Hansa Medical AB (publ) Company Review & Valuation HNSBF
About Hansa Medical AB (publ)
Hansa Medical AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for transplantation and autoimmune diseases. The company's lead drug candidate is Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS), a proprietary antibody-degrading enzyme for kidney transplant patients, as well as for other solid organ transplants and acute autoimmune indications. Its preclinical stage product candidates include Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has licensing agreement with Axis-Shield Diagnostics Ltd. to develop Heparin Binding Protein (HBP)-assay, a novel diagnostic method that predicts severe sepsis in patients with infectious disease symptoms. Hansa Medical AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.
- Lund, Sweden
Primary Stock Exchange Listings